Halaven

Halaven 1mg Injection

Halaven 1mg Injection is used in the treatment of breast cancer. It is used to treat adults with breast cancer that has spread to other parts of the body, and who have already received other ... read more

Halaven Vial Side Effects by Likelihood and Severity

low amount of calcium in the blood low amount of potassium in the blood a significant drop in a certain type of white blood cell called a neutrophil ... read more

Halaven Vial - Uses, Side Effects, and More

Read the Patient Information Leaflet if available from your pharmacist before you start using eribulin and each time you get a refill. If you have any questions, ask your doctor or pharmacist ... read more

Eisai to Present Preclinical and Clinical Research on Eribulin at the 2022 San Antonio Breast Cancer Symposium

Eisai Co., Ltd. announced today that new study results on its in-house discovered and developed anticancer agent eribulin mesylate (HALAVEN, "eribulin") will be presented during the 2022 San ... read more

Eisai Presents Results of Post Hoc Analysis of Eribulin Mesylate (HALAVEN) at the European Society for Medical Oncology (ESMO) Congress 2022

evaluating the efficacy of eribulin mesylate (marketed as HALAVEN) versus other chemotherapies (Treatment of Physician's Choice [TPC], capecitabine, and vinorelbine, respectively) in patients ... read more

Eisai to Present Preclinical and Clinical Research on Eribulin at the 2022 San Antonio Breast Cancer Symposium

NUTLEY, N.J., Dec. 1, 2022 /PRNewswire/ -- Eisai announced today that new study results on its in-house discovered and developed anticancer agent eribulin mesylate (HALAVEN ®, "eribulin") will be ... read more

Eisai to Present Preclinical and Clinical Research on Eribulin at the 2022 San Antonio Breast Cancer Symposium

NUTLEY, N.J., Dec. 1, 2022 /PRNewswire/ -- Eisai announced today that new study results on its in-house discovered and developed anticancer agent eribulin mesylate (HALAVEN ®, "eribulin") will be ... read more

Eisai to Present Preclinical and Clinical Research on Eribulin at the 2022 San Antonio Breast Cancer Symposium

TOKYO, Dec 1, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced today that new study results on its in-house discovered and developed anticancer agent eribulin mesylate (HALAVEN, "eribulin") will ... read more

Eisai to Present Preclinical and Clinical Research on Eribulin at the 2022 San Antonio Breast Cancer Symposium

Real world use of eribulin following treatment with a P13K inhibitor, mostly in people with Hormone Receptor (HR)-positive/HER2-negative metastatic breast cancer ... read more

Eisai to Present Preclinical and Clinical Research on Eribulin at the 2022 San Antonio Breast Cancer Symposium

A magnifying glass. It indicates, "Click to perform a search". A magnifying glass. It indicates, "Click to perform a search". A magnifying glass. It indicates, "Click to perform a search". read more